Cryoablation Combined With Tislelizumab and Chemotherapy as Neoadjuvant and Adjuvant Therapy in Resectable Stage II-IIIB NSCLC

This is a Phase II single-arm study designed to evaluate the efficacy and safety of cryoablation combined with tislelizumab and platinum-based doublet chemotherapy as neoadjuvant therapy, followed by adjuvant tislelizumab therapy in patients with resectable stage II-IIIB non-small cell lung cancer (NSCLC). The study consists of a screening phase, a treatment phase (including the neoadjuvant stage, surgery, and adjuvant stage), a safety follow-up period, and a survival follow-up period.

Trial Details

NCT ID
NCT06939127
Phase
PHASE2
Sponsor
Tianjin Medical University Cancer Institute and Hospital
Status
RECRUITING
Cancer Type
Lung Cancer
Interventions
  • Neoadjuvant Cryoablation Combined with Tislelizumab and Chemotherapy
  • Surgery
  • Adjuvant tislelizumab
Locations (sample)
  • Tianjin, China|39.14222,117.17667

Key Eligibility Criteria

  • Aged ≥18 years at informed consent signing.
  • ECOG performance status of 0 or 1.
  • Histologically confirmed stage II-IIIB NSCLC (AJCC 9th edition).
  • Tumor size ≤5 cm.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lung Cancer Trials on Trialify →